Leptin stimulates the epithelial‑mesenchymal transition and pro‑angiogenic capability of cholangiocarcinoma cells through the miR‑122/PKM2 axis

Peng,Chuang; Sun,Zengpeng; Li,Ou; Guo,Chao; Yi,Weimin; Tan,Zhaoxia; Jiang,Bo

doi:10.3892/ijo.2019.4807

Leptin stimulates the epithelial‑mesenchymal transition and pro‑angiogenic capability of cholangiocarcinoma cells through the miR‑122/PKM2 axis

Authors:
- Chuang Peng
- Zengpeng Sun
- Ou Li
- Chao Guo
- Weimin Yi
- Zhaoxia Tan
- Bo Jiang
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, The People's Hospital of Hunan Province, The First Teaching Hospital of Hunan Normal University, Changsha, Hunan 410005, P.R. China
Published online on: May 21, 2019 https://doi.org/10.3892/ijo.2019.4807
Pages: 298-308

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Leptin is an adipokine minimally known for its activities or underlying mechanisms in cholangiocarcinoma. The present study explored the effects of leptin on the epithelial‑mesenchymal transition (EMT) and pro‑angiogenic capability of cholangiocarcinoma cells, and investigated the underlying mechanisms. Cholangiocarcinoma cells were treated with leptin, and their migration and invasion rates were investigated using Transwell assays. Furthermore, conditioned medium was collected from cholangiocarcinoma cells following leptin treatment and applied to human umbilical vein endothelial cells to assess tube formation. The expression of EMT and pro‑angiogenic factors was examined by reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and western blot analyses. Mechanistically, the function of pyruvate kinase muscle isozyme M2 (PKM2) was assessed in leptin‑induced phenotypes using siRNA targeting PKM2 (si‑PKM2). Bioinformatics screening and luciferase reporter assays were used to reveal microRNA (miR)‑122 as the potential mediator between leptin and PKM2. Finally, the associations between leptin and miR‑122 or PKM2 levels in patients with cholangiocarcinoma were assessed by ELISA and RT‑qPCR. Leptin significantly increased the EMT and pro‑angiogenic capability of cholangiocarcinoma cells, visibly inhibited endogenous miR‑122 expression, and upregulated PKM2. Furthermore, si‑PKM2 inhibited leptin‑induced migration, invasion, EMT‑associated marker expression levels and the pro‑angiogenic capability in cholangiocarcinoma cells. In addition, miR‑122 negatively regulated the expression of PKM2. When applied together with leptin, miR‑122 was sufficient to reverse the multiple malignancy‑promoting effects of leptin. Consistently, the serum leptin level positively correlated with that of PKM2, but negatively with that of miR‑122 in patients with cholangiocarcinoma. Leptin, by downregulating miR‑122 and elevating PKM2 expression, acts as a pleiotropic pro‑malignancy cytokine for cholangiocarcinoma. Therefore, increasing miR‑122 expression and inhibiting PKM2 may be future approaches for cholangiocarcinoma treatment.

View Figures

View References

1	Patel T: Cholangiocarcinoma - controversies and challenges. Nat Rev Gastroenterol Hepatol. 8:189–200. 2011. View Article : Google Scholar : PubMed/NCBI
2	Anderson CD, Pinson CW, Berlin J and Chari RS: Diagnosis and treatment of cholangiocarcinoma. Oncologist. 9:43–57. 2004. View Article : Google Scholar : PubMed/NCBI
3	Gupta GP and Massague J: Cancer metastasis: Building a framework. Cell. 127:679–695. 2006. View Article : Google Scholar : PubMed/NCBI
4	Guarino M, Rubino B and Ballabio G: The role of epithelial-mesenchymal transition in cancer pathology. Pathology. 39:305–318. 2007. View Article : Google Scholar : PubMed/NCBI
5	Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
6	Vaquero J, Guedj N, Clapéron A, Nguyen Ho-Bouldoires TH, Paradis V and Fouassier L: Epithelial-mesenchymal transition in cholangiocarcinoma: From clinical evidence to regulatory networks. J Hepatol. 66:424–441. 2017. View Article : Google Scholar
7	Heerboth S, Housman G, Leary M, Longacre M, Byler S, Lapinska K, Willbanks A and Sarkar S: EMT and tumor metastasis. Clin Transl Med. 4:62015. View Article : Google Scholar : PubMed/NCBI
8	Kelesidis T, Kelesidis I, Chou S and Mantzoros CS: Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med. 152:93–100. 2010. View Article : Google Scholar : PubMed/NCBI
9	Mohammadzadeh G, Ghaffari MA, Bafandeh A and Hosseini SM: Association of serum soluble leptin receptor and leptin levels with breast cancer. J Res Med Sci. 19:433–438. 2014.PubMed/NCBI
10	Karapanagiotou EM, Tsochatzis EA, Dilana KD, Tourkantonis I, Gratsias I and Syrigos KN: The significance of leptin, adiponectin, and resistin serum levels in non-small cell lung cancer (NSCLC). Lung Cancer. 61:391–397. 2008. View Article : Google Scholar : PubMed/NCBI
11	Brown DR, Berkowitz DE and Breslow MJ: Weight loss is not associated with hyperleptinemia in humans with pancreatic cancer. J Clin Endocrinol Metab. 86:162–166. 2001. View Article : Google Scholar : PubMed/NCBI
12	Wallace AM, Sattar N and McMillan DC: Effect of weight loss and the inflammatory response on leptin concentrations in gastrointestinal cancer patients. Clin Cancer Res. 4:2977–2979. 1998.PubMed/NCBI
13	Dutta D, Ghosh S, Pandit K, Mukhopadhyay P and Chowdhury S: Leptin and cancer: Pathogenesis and modulation. Indian J Endocrinol Metab. 16(Suppl 3): S596–S600. 2012. View Article : Google Scholar
14	Morris DL and Rui L: Recent advances in understanding leptin signaling and leptin resistance. Am J Physiol Endocrinol Metab. 297:E1247–E1259. 2009. View Article : Google Scholar : PubMed/NCBI
15	Wei L, Li K, Pang X, Guo B, Su M, Huang Y, Wang N, Ji F, Zhong C, Yang J, et al: Leptin promotes epithelial-mesenchymal transition of breast cancer via the upregulation of pyruvate kinase M2. J Exp Clin Cancer Res. 35:1662016. View Article : Google Scholar : PubMed/NCBI
16	Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL and Cantley LC: The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 452:230–233. 2008. View Article : Google Scholar : PubMed/NCBI
17	Hamabe A, Konno M, Tanuma N, Shima H, Tsunekuni K, Kawamoto K, Nishida N, Koseki J, Mimori K, Gotoh N, et al: Role of pyruvate kinase M2 in transcriptional regulation leading to epithelial-mesenchymal transition. Proc Natl Acad Sci USA. 111:15526–15531. 2014. View Article : Google Scholar : PubMed/NCBI
18	Yang WH, Chen JC, Hsu KH, Lin CY, Wang SW, Wang SJ, Chang YS and Tang CH: Leptin increases VEGF expression and enhances angiogenesis in human chondrosarcoma cells. Biochim Biophys Acta. 1840:3483–3493. 2014. View Article : Google Scholar : PubMed/NCBI
19	Fava G, Alpini G, Rychlicki C, Saccomanno S, DeMorrow S, Trozzi L, Candelaresi C, Venter J, Di Sario A, Marzioni M, et al: Leptin enhances cholangiocarcinoma cell growth. Cancer Res. 68:6752–6761. 2008. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
21	Wong N and Wang X: miRDB: An online resource for microRNA target prediction and functional annotations. Nucleic Acids Res. 43(D1): D146–D152. 2015. View Article : Google Scholar :
22	Li JH, Liu S, Zhou H, Qu LH and Yang JH: starBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 42(D1): D92–D97. 2014. View Article : Google Scholar
23	Candela r ia PV, Rampoldi A, Ha rbuza r iu A and Gonzalez-Perez RR: Leptin signaling and cancer chemoresistance: Perspectives. World J Clin Oncol. 8:106–119. 2017. View Article : Google Scholar
24	Park J and Scherer PE: Leptin and cancer: From cancer stem cells to metastasis. Endocr Relat Cancer. 18:C25–C29. 2011. View Article : Google Scholar : PubMed/NCBI
25	Gao C, Patel CJ, Michailidou K, Peters U, Gong J, Schildkraut J, Schumacher FR, Zheng W, Boffetta P, Stucker I, et al the Colorectal Transdisciplinary Study (CORECT); Discovery, Biology and Risk of Inherited Variants in Breast Cancer (DRIVE); Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE); Follow-up of Ovarian Cancer Genetic Association and Interaction Studies (FOCI); and Transdisciplinary Research in Cancer of the Lung (TRICL): Mendelian randomization study of adiposity-related traits and risk of breast, ovarian, prostate, lung and colorectal cancer. Int J Epidemiol. 45:896–908. 2016. View Article : Google Scholar : PubMed/NCBI
26	Kyrgiou M, Kalliala I, Markozannes, Gunter MJ, Paraskevaidis E, Gabra H, Martin-Hirsch P and Tsilidis KK: Adiposity and cancer at major anatomical sites: Umbrella review of the literature. BMJ. 356:j4772017. View Article : Google Scholar : PubMed/NCBI
27	Ayoub N, Alkhatatbeh M, Jibreel M and Ababneh M: Analysis of circulating adipokines in patients newly diagnosed with solid cancer: Associations with measures of adiposity and tumor characteristics. Oncol Lett. 13:1974–1982. 2017. View Article : Google Scholar : PubMed/NCBI
28	Stattin P, Lukanova A, Biessy C, Söderberg S, Palmqvist R, Kaaks R, Olsson T and Jellum E: Obesity and colon cancer: Does leptin provide a link? Int J Cancer. 109:149–152. 2004. View Article : Google Scholar : PubMed/NCBI
29	Wang D, Gao L, Gong K, Chai Q and Wang G: Increased serum leptin level in overweight patients with colon carcinoma: A cross-sectional and prospective study. Mol Clin Oncol. 6:75–78. 2017. View Article : Google Scholar : PubMed/NCBI
30	Bolukbas FF, Kilic H, Bolukbas C, Gumus M, Horoz M, Turhal NS and Kavakli B: Serum leptin concentration and advanced gastrointestinal cancers: A case controlled study. BMC Cancer. 4:292004. View Article : Google Scholar : PubMed/NCBI
31	Li JS, Han TJ, Jing N, Li L, Zhang XH, Ma FZ and Liu JY: Obesity and the risk of cholangiocarcinoma: A meta-analysis. Tumour Biol. 35:6831–6838. 2014. View Article : Google Scholar : PubMed/NCBI
32	Nitta T, Mitsuhashi T, Hatanaka Y, Miyamoto M, Oba K, Tsuchikawa T, Suzuki Y, Hatanaka KC, Hirano S and Matsuno Y: Prognostic significance of epithelial-mesenchymal transition-related markers in extrahepatic cholangiocarcinoma: Comprehensive immunohistochemical study using a tissue microarray. Br J Cancer. 111:1363–1372. 2014. View Article : Google Scholar : PubMed/NCBI
33	Clapéron A, Mergey M, Nguyen Ho-Bouldoires TH, Vignjevic D, Wendum D, Chrétien Y, Merabtene F, Frazao A, Paradis V, Housset C, et al: EGF/EGFR axis contributes to the progression of cholangiocarcinoma through the induction of an epithelial-mesenchymal transition. J Hepatol. 61:325–332. 2014. View Article : Google Scholar : PubMed/NCBI
34	Yan D, Avtanski D, Saxena NK and Sharma D: Leptin-induced epithelial-mesenchymal transition in breast cancer cells requires β-catenin activation via Akt/GSK3- and MTA1/Wnt1 protein-dependent pathways. J Biol Chem. 287:8598–8612. 2012. View Article : Google Scholar : PubMed/NCBI
35	Feng H, Liu Q, Zhang N, Zheng L, Sang M, Feng J, Zhang J, Wu X and Shan B: Leptin promotes metastasis by inducing an epithelial-mesenchymal transition in A549 lung cancer cells. Oncol Res. 21:165–171. 2013. View Article : Google Scholar
36	Wei X, Liu Y, Gong C, Ji T, Zhou X, Zhang T, Wan D, Xu S, Jin P, Yang X, et al: Targeting leptin as a therapeutic strategy against ovarian cancer peritoneal metastasis. Anticancer Agents Med Chem. 17:1093–1101. 2017. View Article : Google Scholar
37	Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polymeneas G and Voros D: Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog. 52:297–303. 2013. View Article : Google Scholar
38	Wu C, Zhang J, Cao X, Yang Q and Xia D: Effect of mir-122 on human cholangiocarcinoma proliferation, invasion, and apoptosis through P53 expression. Med Sci Monit. 22:2685–2690. 2016. View Article : Google Scholar : PubMed/NCBI
39	Leyva-Illades D, McMillin M, Quinn M and Demorrow S: Cholangiocarcinoma pathogenesis: Role of the tumor microenvironment. Transl Gastrointest Cancer. 1:71–80. 2012.PubMed/NCBI
40	Tahergorabi Z and Khazaei M: Leptin and its cardiovascular effects: Focus on angiogenesis. Adv Biomed Res. 4:792015. View Article : Google Scholar : PubMed/NCBI
41	Wang Y, Xing QF, Liu XQ, Guo ZJ, Li CY and Sun G: miR-122 targets VEGFC in bladder cancer to inhibit tumor growth and angiogenesis. Am J Transl Res. 8:3056–3066. 2016.PubMed/NCBI
42	Azoitei N, Becher A, Steinestel K, Rouhi A, Diepold K, Genze F, Simmet T and Seufferlein T: PKM2 promotes tumor angiogenesis by regulating HIF-1α through NF-κB activation. Mol Cancer. 15:32016. View Article : Google Scholar
43	Li L, Zhang Y, Qiao J, Yang JJ and Liu ZR: Pyruvate kinase M2 in blood circulation facilitates tumor growth by promoting angiogenesis. J Biol Chem. 289:25812–25821. 2014. View Article : Google Scholar : PubMed/NCBI